ALNY: AMVUTTRA Holds the Line as Q1 2026 Sets the Stage for a Long-Horizon Pipeline

Quarter at a glance

Alnylam Pharmaceuticals reported its first quarter of 2026 with a strong top-line signal and a reaffirmed revenue trajectory. The company disclosed:

• Global net product revenues: $1,036 million, up 121% year over year.
• Total TTR net product revenues: $910 million, up 153% vs. Q1 2025, driven by AMVUTTRA and ONPATTRO.
• AMVUTTRA ( vutrisiran ) contributed $890 million in TTR net product revenues; ONPATTRO contributed $20 million.
• Guidance reaffirmed for 2026: Combined net product revenues of $4.9–$5.3 billion; Total TTR net product revenues of $4.4–$4.7 billion.
• Near-term pipeline updates: New data from ACC.26 supporting use of TRITON-CM candidate nucresiran in ATTR-CM.

What this means for Alnylam and its peers

The quarter underscores the resilience of Alnylam’s core products. AMVUTTRA’s uptake in ATTR-CM continues to be the anchor, delivering the bulk of the TTR revenue stream, while ONPATTRO provides a smaller, but still meaningful, contribution. The 153% growth in total TTR revenues versus a year ago suggests that, despite macro questions about drug pricing and payer dynamics, patient access and prescribing momentum remain favorable for these assets.

The revenue forecast is the sentence you’ll want to read twice. A combined net product revenues target of nearly $5 billion for 2026 signals confidence that the company can compound top-line growth even as it mobilizes a broader pipeline. The ACC.26 data on nucresiran—an investigational next-generation TTR silencer—adds optionality beyond the mature AMVUTTRA/ONPATTRO franchise and could re-rate the stock if the phase 3 data translate into meaningful clinical and commercial benefits.

From a sector lens, Alnylam’s results reinforce the idea that RNAi players are increasingly measured by a two-track narrative: sell-through of established antisense-like products and the optionality of late-stage assets that can meaningfully move the revenue needle in later years. For peers, the question is whether their pipelines can deliver similar uplift in the second half of 2026 and whether payer acceptance can sustain, or even expand, the revenue forecast trajectories.

Risks and what the market will be watching

Important caveats remain. The press release highlights revenue and pipeline milestones but does not publish quarterly or year-to-date EPS figures in this excerpt, so the EPS consensus metrics are currently opaque. Investors will be listening for potential earnings surprises or disappointments in subsequent quarters as R&D and SG&A spend weigh on near-term profitability. The robustness of the 2026 revenue forecast will hinge on continued adoption of AMVUTTRA and ONPATTRO, stability in payer coverage, and any shifts in the competitive landscape. Pipeline milestones—especially the second-half readouts—could either validate the higher revenue path or raise questions about execution risk if milestone timing slips.

Takeaways for investors

• Alnylam’s Q1 2026 shows durable top-line performance, anchored by AMVUTTRA and ONPATTRO within the TTR portfolio.
• The reaffirmed 2026 revenue forecast suggests management expects continued market uptake and favorable pricing/payer dynamics for key products.
• The pipeline, highlighted by nucresiran and multiple ACC.26 references, provides optionality that could drive longer-horizon earnings if late-stage data translate to additional approvals or label expansions.
• For sector peers, the message is that a credible, data-driven update on a mature asset line can coexist with meaningful investment in next-gen programs—expect similar balance sheets to be scrutinized for both near-term EPS signals and long-run revenue potential.